Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway
News provided by
Share this article
Share this article
SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C financing. The company anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP. The Series C financing was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. With the financing, Dr. Norman Zhou of Boxer Capital has joined the board of directors at Vivace.